Combinations of two or three hepatitis C virus direct-acting antiviral drugs taken for 8-24 weeks can cure more than 90% of people treated. However, this breakthrough in clinical medicine comes at a cost.
To investigate the issue of reinfection, researchers at the Vancouver Infectious Disease Clinic reviewed the medical records of several hundred people who had been treated and cured of HCV. They found that cases of reinfection were very low.
It is possible that acid-reducing agents could reduce the absorption of ledipasvir in Harvoni and, therefore, its ability to help cure HCV infection.
In a clinical trial where Epclusa was used along with the broad-spectrum antiviral drug ribavirin, the combination was able to cure 91% of participants who needed retreatment after their previous regimen had failed.
In a study sponsored by Gilead Sciences called Astral-5, researchers tested the fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) in 106 people who were coinfected with hepatitis C virus (HCV) and HIV.
The fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) has been evaluated for possible and potential interactions with other drugs.
Sofosbuvir + Velpatasvir (Epclusa) -- Improvements in Quality of Life, Energy and Emotional and Mental Health
Researchers found that among participants who received sofosbuvir + velpatasvir (Epclusa), aspects of mental health assessed began to improve significantly by the fourth week of the study.
Researchers at the University of Toronto conducted an intensive review of 37 published studies in which interferon was used as treatment for HCV infection. Among participants who were cured, 3% subsequently developed liver cancer. Among participants ...
Doctors in Barcelona recently reported an unexpected increase in liver cancer recurrence in people who had been or who are being treated for chronic hepatitis C virus (HCV) infection with new potent all-oral medicines called direct acting antivirals ...
Spurred by reports from other cities, doctors in Bologna, Italy, have reviewed their database to assess possible risk factors for liver cancer development and recurrence in 344 participants who were treated for hepatitis C virus (HCV) infection with ...